Restricted accessReview articleFirst published online 2025
Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Agitation is a frequent and distressing neuropsychiatric symptom in patients with Alzheimer’s disease (AD), often leading to increased caregiver burden, institutionalization, and healthcare costs. While antipsychotics are commonly prescribed, their use is limited by safety concerns. Selective serotonin reuptake inhibitors (SSRIs), such as citalopram and escitalopram, have emerged as alternative treatments with a more favorable safety profile. This study aimed to evaluate the efficacy and safety of these agents in the management of agitation in AD.
Methods
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing citalopram or escitalopram with placebo or other pharmacological treatments in older adults with AD and clinically defined agitation. Primary outcomes included changes in agitation severity, assessed by the Neuropsychiatric Inventory–Clinician Rating (NPI-C) and the Neurobehavioral Rating Scale (NBRS). Secondary outcomes included cognitive function (MMSE), anxiety symptoms, and adverse events. Standardized mean difference (SMD) and risk ratio (RR) were pooled using a random-effects model.
Results
Four RCTs comprising 502 patients were included. Pooled analysis showed no significant improvement in agitation severity (SMD –0.67; 95% CI –2.58, 1.25; I2 = 98.3%) or cognitive outcomes (SMD 2.43; 95% CI –2.55, 7.41). Rates of serious adverse events (RR 0.85; 95% CI 0.50, 1.45) and treatment discontinuation (RR 1.05; 95% CI 0.80, 1.37) were similar between groups. However, SSRI use was associated with an increased risk of falls (RR 1.78; 95% CI 1.15, 2.75; I2 = 0%).
Conclusion
Escitalopram and citalopram do not significantly reduce agitation in AD but are generally well tolerated. Increased fall risk warrants cautious clinical use.
CummingsJMintzerJBrodatyH, et al.Agitation in cognitive disorders: International psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27:7-17. doi:10.1017/S1041610214001963
2.
KalesHCGitlinLNLyketsosCG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. doi:10.1136/bmj.h369
3.
KalesHCGitlinLNLyketsosCGDetroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762-769. doi:10.1111/jgs.12730
4.
KalesHCKernVKimHMBlazekMC. Moving evidence-informed assessment and management of behavioral and psychological symptoms of dementia into the real world: training family and staff caregivers in the DICE approach. Am J Geriatr Psychiatry. 2020;28:1248-1255. doi:10.1016/j.jagp.2020.08.008
5.
GitlinLNKalesHCLyketsosCG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020-2029. doi:10.1001/jama.2012.36918
6.
LanctotKLAmatniekJAncoli-IsraelS, et al.Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms. Alzheimers Dement (N Y). 2017;3:440-449. doi:10.1016/j.trci.2017.07.001
7.
TrilloLDasDHsiehW, et al.Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37:1363-1379. doi:10.1016/j.neubiorev.2013.05.008
8.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet. 2020;396:413-446. doi:10.1016/S0140-6736(20)30367-6
9.
LivingstonGHuntleyJLiuKY, et al.Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet. 2024;404:572-628. doi:10.1016/S0140-6736(24)01296-0
10.
KongpakwattanaKSawangjitRTawankanjanachotIBellJSHilmerSNChaiyakunaprukN. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84:1445-1456. doi:10.1111/bcp.13604
11.
ScarmeasNBrandtJAlbertM, et al.Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601-1608. doi:10.1001/archneur.62.10.1601
12.
CloutierMGauthier-LoiselleMGagnon-SanschagrinP, et al.Institutionalization risk and costs associated with agitation in Alzheimer's disease. Alzheimers Dement (N Y). 2019;5:851-861. doi:10.1016/j.trci.2019.10.004
13.
ZhaoYKuoTCWeirSKramerMSAshAS. Healthcare costs and utilization for medicare beneficiaries with Alzheimer's. BMC Health Serv Res. 2008;8:108. doi:10.1186/1472-6963-8-108
14.
LivingstonGSommerladAOrgetaV, et al.Dementia prevention, intervention, and care. Lancet. 2017;390:2673-2734. doi:10.1016/S0140-6736(17)31363-6
15.
WangJYuJTWangHF, et al.Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86:101-109. doi:10.1136/jnnp-2014-308112
16.
SchneiderLSDagermanKInselPS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210. doi:10.1097/01.JGP.0000200589.01396.6d
17.
MokPLHCarrMJGuthrieB, et al.Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. doi:10.1136/bmj-2023-076268
18.
HerrmannNLanctotKL. Do atypical antipsychotics cause stroke?CNS Drugs. 2005;19:91-103. doi:10.2165/00023210-200519020-00001
19.
SeitzDPAdunuriNGillSSGruneirAHerrmannNRochonP. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2011:CD008191. doi:10.1002/14651858.CD008191.pub2
20.
MaHHuangYCongZ, et al.The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915-937. doi:10.3233/JAD-140579
21.
LeeDSlomkowskiMHeftingN, et al.Brexpiprazole for the treatment of agitation in alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80:1307-1316. doi:10.1001/jamaneurol.2023.3810
22.
GrossbergGTKohegyiEMergelV, et al.Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-Week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28:383-400. doi:10.1016/j.jagp.2019.09.009
23.
NakamuraYAdachiJHirotaN, et al.Brexpiprazole treatment for agitation in Alzheimer's dementia: a randomized study. Alzheimers Dement. 2024;20:8002-8011. doi:10.1002/alz.14282
24.
ReusVIFochtmannLJEylerAE, et al.The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Focus (Am Psychiatr Publ). 2017;15:81-84. doi:10.1176/appi.focus.15107
25.
FazioSPaceDMaslowKZimmermanSKallmyerB. Alzheimer's association dementia care practice recommendations. Gerontol. 2018;58:S1-S9. doi:10.1093/geront/gnx182
26.
LeeDClarkEDAntonsdottirIMPorsteinssonAP. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2023;24:691-703. doi:10.1080/14656566.2023.2195539
27.
BallardCCorbettAHowardR. Prescription of antipsychotics in people with dementia. Br J Psychiatry. 2014;205:4-5. doi:10.1192/bjp.bp.113.128710
28.
PorsteinssonAPDryeLTPollockBG, et al.Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-691. doi:10.1001/jama.2014.93
29.
PorsteinssonAPAntonsdottirIM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017;18:611-620. doi:10.1080/14656566.2017.1307340
30.
WangPSSchneeweissSAvornJ, et al.Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341. doi:10.1056/NEJMoa052827
31.
LeonpacherAKPetersMEDryeLT, et al.Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173:473-480. doi:10.1176/appi.ajp.2016.15020248
32.
OrgetaVTabetNNilforooshanRHowardR. Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58:725-733. doi:10.3233/JAD-161247
33.
PageMJMoherDBossuytPM, et al.PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160
34.
HigginsJPTThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions. 1st ed.Wiley; 2019.
35.
McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984;34:939-944. doi:10.1212/wnl.34.7.939
36.
CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJ. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314. doi:10.1212/wnl.44.12.2308
37.
de MedeirosKRobertPGauthierS, et al.The neuropsychiatric inventory-clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22:984-994. doi:10.1017/S1041610210000876
38.
LevinHSHighWMGoetheKE, et al.The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50:183-193. doi:10.1136/jnnp.50.2.183
39.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198. doi:10.1016/0022-3956(75)90026-6
40.
SterneJACSavovicJPageMJ, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
41.
RajjiTKBakshSNShadeDM, et al.Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial. Nat Med. 2025;31:1586-1591. doi:10.1038/s41591-025-03569-y
42.
BarakYPlopskiITadgerSPaleacuD. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23:1515-1519. doi:10.1017/S1041610211000743
43.
PollockBGMulsantBHRosenJ, et al.A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942-952. doi:10.1097/JGP.0b013e3180cc1ff5
44.
BalduzziSRückerGSchwarzerG. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153-160. doi:10.1136/ebmental-2019-300117
45.
DryeLTSpraggDDevanandDP, et al.Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014;9:e98426. doi:10.1371/journal.pone.0098426
46.
CummingsJPintoLCCruzM, et al.Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition. Am J Geriatr Psychiatry. 2020;28:1256-1269. doi:10.1016/j.jagp.2020.09.002
47.
NythALGottfriesCG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894-901. doi:10.1192/bjp.157.6.894
48.
SiddiqueHHynanLSWeinerMF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry. 2009;70:915-918. doi:10.4088/JCP.08m04828
49.
Mahmoudzadeh KhaliliSSimpkinsCYangF. A meta-analysis of fall risk in older adults with Alzheimer's disease. J Am Med Dir Assoc. 2024;25:781-788. doi:10.1016/j.jamda.2024.01.005
50.
AgaVM. When and how to treat agitation in Alzheimer's disease dementia with citalopram and escitalopram. Am J Geriatr Psychiatry. 2019;27:1099-1107. doi:10.1016/j.jagp.2019.04.016
51.
GebaraMALipseyKLKarpJFNashMCIaboniALenzeEJ. Cause or effect? Selective serotonin reuptake inhibitors and falls in older adults: a systematic review. Am J Geriatr Psychiatry. 2015;23:1016-1028. doi:10.1016/j.jagp.2014.11.004
52.
CouplandCDhimanPMorrissRArthurABartonGHippisley-CoxJ. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. doi:10.1136/bmj.d4551
53.
MazharFPozziMGentiliM, et al.Association of hyponatraemia and antidepressant drugs: a pharmacovigilance-pharmacodynamic assessment through an analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. CNS Drugs. 2019;33:581-592. doi:10.1007/s40263-019-00631-5
54.
BrodatyHAmesDSnowdonJ, et al.A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143. doi:10.4088/jcp.v64n0205
55.
HsuTWStubbsBLiangCS, et al.Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: a systematic review and meta-analysis. Ageing Res Rev. 2021;69:101362. doi:10.1016/j.arr.2021.101362
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
